feed,title,long_url,short_url
Benzinga,Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment,https://www.benzinga.com/pressreleases/20/09/g17694065/intellia-therapeutics-presents-new-preclinical-data-showing-persistent-in-vivo-editing-and-durabil,https://j.mp/3jezcJQ
